Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
about
The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancerGenetics of myeloproliferative neoplasmsStem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry.Lnk constrains myeloproliferative diseases in mice.Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.LNK (SH2B3): paradoxical effects in ovarian cancer.Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cellsPrevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaSH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosisJAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsGenetic loss of SH2B3 in acute lymphoblastic leukemia.Erythropoietin receptor response circuitsA structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis.Role of the adaptor protein LNK in normal and malignant hematopoiesis.Molecular biology of Philadelphia-negative myeloproliferative neoplasmsGenetic and epigenetic alterations of myeloproliferative disorders.Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia.LNK mutations and myeloproliferative disorders.The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.Isogenic Cellular Systems Model the Impact of Genetic Risk Variants in the Pathogenesis of Type 1 Diabetes.Selective Interference Targeting of Lnk in Umbilical Cord-Derived Late Endothelial Progenitor Cells Improves Vascular Repair, Following Hind Limb Ischemic Injury, via Regulation of JAK2/STAT3 Signaling.SH2B proteins bind JAK2Cytosolic lysine residues enhance anterograde transport and activation of the erythropoietin receptor.Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling.Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?Cytokine Receptors
P2860
Q26770682-E8EAF997-EDC3-4802-9947-F7B02B7AF003Q26823651-28658214-DC38-4C54-B8C0-1B566002702AQ31156217-02EE20F6-DDA4-43FF-9774-1A57CF8A4A19Q33882944-415C2425-6770-428F-9224-AFEEC4898D4CQ33997280-556F1840-3AF4-47ED-936A-2D554F3BD1F8Q34150008-05A4A883-5F0F-40C3-942B-38F10C65954AQ34166859-D290603C-73BA-42A6-B089-FD08D5A1CAFFQ34302585-3A5659C9-D41E-4BCF-B5E9-E2865460A023Q34629928-62730E93-FAF2-4752-A165-F165DA366883Q36005362-AAB7F6F0-2D02-4DE1-9A8C-99AD4F8B715EQ36261941-0D6B4F17-5CF7-4667-A9A6-862220D0CDF5Q36333540-F3868C32-1E57-479A-ADE9-019F1A06B527Q36352535-C86FFAC0-7BBB-41BF-A562-F76E3A7DF91CQ36901651-25B5761A-7239-479F-AA2B-6BE202E84FC5Q36907588-AC29AE84-9B96-48D0-A3B8-9C9CF5793AA6Q37168138-986B8060-E29C-44D5-953E-E97525850B46Q37215146-7A49CFD0-B603-462D-82CF-E264A97E415CQ37696206-DC93F12F-2156-49D1-B68C-48D67920B6ADQ37921836-B13A6F84-2D79-44EF-B2DF-D3F0D92F8C09Q38044625-394AE9C7-97F8-4F4F-B626-2D7A7B339E2DQ38050407-556ACB04-4917-4606-89D6-E47B89D4A2FDQ38050756-1D74DF58-103D-4B76-87A3-291539679221Q38066786-28ABB9B9-C1AE-456D-AA50-F9F96785BDA5Q38102578-23E756B6-EFC7-455E-931B-65E052B3F590Q38667486-3465D7E7-B650-4DD2-ACDF-23A3053C238AQ39292396-148A17D0-1777-4B90-88E0-5B296564C4EAQ39788785-8B1B5CE6-99FB-4E22-88C0-2194E1476C28Q42870230-ACBABA89-5EB2-4604-A871-77B18E53960CQ42931701-7780AC1C-252C-4B75-BBF9-739A7B16AF7FQ45818945-3D967CA9-A8FF-41E7-BB87-FBBCF5E8D7D2Q48146328-B8FC7649-9FD0-465A-9A19-16D9B0674964Q50291343-3A13BE57-9832-4711-B424-4E68E9D29934Q51889679-F822C0D9-5660-4182-B23D-2B78EA364037Q52655332-BA49608B-AE67-42C6-BC6A-92F14BDE6D10Q54574818-741C6667-92D4-4586-A19D-F2904E492208Q57252653-36DB7947-83B8-444E-8762-BA6DD6181CFD
P2860
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
@en
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
@nl
type
label
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
@en
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
@nl
prefLabel
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
@en
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
@nl
P2093
P2860
P356
P1476
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
@en
P2093
H Phillip Koeffler
Hongtao Xing
Saskia Gueller
Sigal Gery
P2860
P304
P356
10.1189/JLB.0908575
P577
2009-03-17T00:00:00Z